48 citations
,
August 2022 in “Chemical Biology & Drug Design” This review outlines computational strategies, including chemogenomics and drug repositioning, for coronavirus drug discovery and reports no new clinical findings; the authors highlight the advantages of these methods in rapidly identifying therapeutic candidates.
30 citations
,
October 2020 in “Nature Communications” This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
32 citations
,
March 2020 in “Drug Design Development and Therapy” This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.
5 citations
,
January 2018 in “Italian journal of dermatology and venereology” This study discusses that while the precise mechanism of minoxidil is not fully understood, its efficacy in stimulating hair growth and treating androgenetic alopecia is well-supported, with evidence showing it increases hair count and hair follicle size in treated patients.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
24 citations
,
March 2017 in “Journal of The European Academy of Dermatology and Venereology” This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.
33 citations
,
January 2016 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.
29 citations
,
September 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.
66 citations
,
May 2012 in “Scientific Reports” This study demonstrated that bioengineered hair follicles reconstituted from embryonic skin cells and transplanted into hosts can restore physiological hair functions, suggesting potential applications for treating alopecia.
179 citations
,
April 2012 in “Nature Communications” This study demonstrates the potential of using bioengineered follicles from adult tissue-derived stem cells for fully functional hair regeneration, illustrating possible applications in organ replacement therapy.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.
111 citations
,
October 2008 in “Nature Genetics” In their study, Tim Spector and colleagues identified a new genetic association at chromosome 20p11.22 with male-pattern baldness, confirmed by the increased risk when combined with a known androgen receptor gene variant.
62 citations
,
April 2004 in “Expert Opinion on Pharmacotherapy” This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.
229 citations
,
August 2002 in “Experimental Gerontology” This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.
32 citations
,
April 1999 in “Expert Opinion on Investigational Drugs” Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.
70 citations
,
April 1990 in “Journal of The American Academy of Dermatology” Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.
